A possible anti-proliferative and anti-metastatic effect of irradiated riboflavin in solid tumours

Cancer Letters

Volumn 258, Issue 1, 2007, Pages 126-134

  de Souza Queiroz, Karla Cristiana ^a   Zambuzzi, Willian Fernando ^a   Santos de Souza, Ana Carolina ^a   da Silva, Rodrigo Augusto ^a   Machado, Daisy ^a   Justo, Giselle Zenker ^a,b   Carvalho, Hernandes F ^a   Peppelenbosch, Maikel P ^c   Ferreira, Carmen Veríssima ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Apoptosis; Prostate cancer; Riboflavin

Indexed keywords

FAS ANTIGEN; FAS LIGAND; PROTEINASE; RIBOFLAVIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; VASCULOTROPIN;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER MODEL; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG MECHANISM; ENZYMATIC DEGRADATION; HUMAN; HUMAN CELL; IRRADIATION; MALE; METASTASIS INHIBITION; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RAT; SOLID TUMOR; UPREGULATION;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CASPASES; CELL PROLIFERATION; CELLS, CULTURED; HEPATOCYTES; HUMANS; MALE; NEOPLASMS, HORMONE-DEPENDENT; PHOTOSENSITIZING AGENTS; PROSTATE; PROSTATIC NEOPLASMS; RATS; RIBOFLAVIN;

EID: 35348931540     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2007.08.024     Document Type: Article

References (31)

1. Hisatake J., O'Kelly J., Uskokovic M.R., Tomoyasu S., and Koeffler P. Novel vitamin D3 analog, 21-(3-methyl-3-hydroxy-butyl)-19-nor D3, that modulates cell growth, differentiation apoptosis, cell cycle, and induction of PTEN in leukemic cells. Blood 97 (2001) 2427-2433
2. Tsuzuki S., Kitajima K., Nakano T., Glasow A., Zelent A., and Enver T. Cross talk between retinoic acid signaling and transcription factor GATA-2. Mol. Cell. Biol. 24 (2004) 6824-6836
3. Trump D.L., Muindi J., Fakih M., Yu W.D., and Johnson C.S. Vitamin D compounds: clinical development as cancer therapy and prevention agents. Anticancer Res. 26 (2006) 2551-2556
4. de Souza A.C.S., Kodach L.L., Gadelha F.R., Bos C.L., Cavagis A.D.M., Aoyama H., Peppelenbosch M.P., and Ferreira C.V. A promising action of riboflavin as a mediator of leukaemia cell death. Apoptosis 11 (2006) 1761-1771
5. Skinner H.G., Michaud D.S., Giovannucci E., Willett W.C., Colditz G.A., and Fuchs C.S. Vitamin D intake and the risk for pancreatic cancer in two cohort studies. Cancer Epidemiol. Biomarkers Prev. 15 (2006) 1688-1695
6. Sobel R.E., and Sadar M.D. Cell lines used in prostate cancer research: a compendium of old and new lines-part 1. J. Urol. 173 (2005) 342-359
7. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assay. J. Immunol. Methods 65 (1983) 55-63
8. Hartree E.F. Determination of proteins: a modification of Lowry method that give a linear photometric response. Anal. Biochem. 48 (1972) 422-427
9. de Souza A.P., Gerlach R.F., and Line S.R. Inhibition of human gingival gelatinases (MMP-2 and MMP-9) by metal salts. Dent. Mater. 16 (2000) 103-108
10. Wollensak G., Spoerl E., Wilsch M., and Seiler T. Keratocyte apoptosis after corneal collagen cross-linking using riboflavin/UVA treatment. Cornea 23 (2004) 43-49
11. Corbin III F. Pathogen inactivation of blood components: current status and introduction of an approach using riboflavin as a photosensitizer. Int. J. Hematol. 2 (2002) 253-257
12. Hardwick C.C., Herivel T.R., Hernandez S.C., Ruane P.H., and Goodrich R.P. Separation, identification and quantification of riboflavin and its photoproducts in blood products using high-performance liquid chromatography with fluorescence detection: a method to support pathogen reduction technology. Photochem. Photobiol. 80 (2004) 609-615
13. Costa-Pereira A.P., and Cotter T.G. Camptothecin sensitizes androgen-independent prostate cancer cells to anti-Fas-induced apoptosis. Br. J. Cancer 80 (1999) 371-378
14. Hyer M.L., Voelkel-Johnson C., Rubinchik S., Don J., and Norris J.S. Intracellular Fas ligand expression causes Fas-mediated apoptosis in human prostate cancer cells resistant to monoclonal antibody-induced apoptosis. Mol. Ther. 2 (2000) 348-358
15. Bertram J., Peacock J.W., Tan C., Mui A.L., Chung S.W., Gleave M.E., Dedhar S., Cox M.E., and Ong C.J. Inhibition of the phosphatidylinositol 3′-kinase pathway promotes autocrine Fas-induced death of phosphatase and tensin homologue-deficient prostate cancer cells. Cancer Res. 66 (2006) 4781-4788
16. Siskind L.J. Mitochondrial ceramide and the induction of apoptosis. J. Bioenerg. Biomem. 37 (2005) 143-153
17. Cremesti A.E., Goni F.M., and Kolesnick R. Role of sphingomyelinase and ceramide in modulating rafts: do biophysical properties determine biologic outcome?. FEBS Lett. 531 (2002) 47-53
18. Huang S.T., Yang R.C., Chen M.Y., and Pang J.H. Phyllanthus urinaria induces the Fas receptor/ligand expression and ceramide-mediated apoptosis in Hl60 cells. Life Sci. 75 (2004) 339-351
19. Miyaji M., Jin Z.X., Yamaoka S., Amakawa R., Fukuhara S., Sato S.B., Kobayashi T., Domae N., Mimori T., Bloom E.T., Okazaki T., and Umehara H. Role of membrane sphingomyelin and ceramide in platform formation for Fas-mediated apoptosis. J. Exp. Med. 202 (2005) 249-259
20. Rotolo J.A., Zhang J., Donepudi M., Lee H., Fuks Z., and Kolesnick R. Caspase-dependent and-independent activation of acid sphingomyelinase signaling. J. Biol. Chem. 280 (2005) 26425-26434
21. Verheij M., Bose R., Lin X.H., Yao B., Jarvis W.D., Grant S., Birrer M.J., Szabo E., Zon L.I., Kyriakis J.M., Haimovitz-Friedman A., Fuks Z., and Kolesnick R.N. Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis. Nature 380 (1996) 75-79
22. Hetz C.A., Hunn M., Rojas P., Torres V., Leyton L., and Quest A.F. Caspase-dependent initiation of apoptosis and necrosis by the Fas receptor in lymphoid cells: onset of necrosis is associated with delayed ceramide increase. J. Cell Sci. 115 (2002) 4671-4683
23. Bertollo C.M., Oliveira A.C., Rocha L.T., Costa K.A., Nascimento E.B., and Coelho M.M. Characterization of the antinociceptive and anti-inflammatory activities of riboflavin in different experimental models. Eur. J. Pharmacol. 547 (2006) 184-191
24. Aoyama H., Silva T.M.A., Miranda M.A., and Ferrerira C.V. Proteínas tirosina fosfatases: propriedades e funções biológicas. Quim. Nova 26 (2003) 896-900
25. McCluskey A., Ackland S.P., Bowyer M.C., Baldwin M.L., Garner J., Walkom C.C., and Sakoff J.A. Cantharidin analogues: synthesis and evaluation of growth inhibition in a panel of selected tumor cell lines. Bioorg. Chem. 31 (2003) 68-79
26. Ferreira C.V., Justo G.Z., Souza A.C.S., Queiroz K.C.S., Zambuzzi W.F., Aoyama H., and Peppelenbosch M.P. Natural compounds as a source of protein tyrosine phosphatase inhibitors: application to the rational design of small-molecule derivatives. Biochimie 88 (2006) 1859-1873
27. Choueiri M.B., Tu S.M., Yu-Lee L.Y., and Lin S.H. The central role of osteoblasts in the metastasis of prostate cancer. Cancer Metastasis Rev. 25 (2006) 601-609
28. Deryugina E.I., and Quigley J.P. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev. 25 (2006) 9-34
29. Justo G.Z., and Ferreira C.V. Coagulation and cancer therapy: the potential of natural compounds. Curr. Genomics 6 (2005) 461-469
30. Ye J., and Yuan L. Inhibition of p38 MAPK reduces tumor conditioned medium-induced angiogenesis in co-cultured human umbilical vein endothelial cells and fibroblasts. Biosci. Biotechnol. Biochem. 71 (2007) 1162-1169
31. Perumal S.S., Shanthi P., and Sachdanandam P. Augmented efficacy of tamoxifen in rat breast tumorigenesis when gavaged along with riboflavin, niacin, and CoQ10: effects on lipid peroxidation and antioxidants in mitochondria. Chem. Biol. Interact. 152 (2005) 49-58